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Recently, a new synthetic, absorbable surgical sealant
has proved biocompatibility and effectiveness as a
dural6 and lung7 sealant in a canine model. On this
basis, we first investigated the effects of this adhesive
on healthy bronchial and lung tissues in a pig model and
then conducted a prospective randomized clinical study,
investigating the safety and efficacy of this adhesive to
reduce parenchymal air leaks after lung resections.
Materials and methods
Experimental study. Fifteen large white pigs (25-40 kg)
underwent a left upper lobectomy, performed by 2 of us (P.M.
and J.W.). The lung fissure was always stapled, and all areas
of parenchymal dissections were treated with the surgical
sealant; the bronchial stump was randomly stapled (group 1),
stapled and sealed (group 2), or sealed only (group 3). Each
study group included 5 animals. All animals received care in
compliance with the “Principles of Laboratory Animal Care”
formulated by the National Society for Medical Research and
the “Guide for the Care and Use of Laboratory Animals” for-
mulated by the National Academy of Sciences (NIH publica-
tion No. 85-23, revised 1985).
General anesthesia was induced with ketamine hydrochlo-
A ir leaks occur at pulmonary tissue sites that havebeen dissected during surgical resection and/or
manipulation. Most small-flow air leaks, resulting from
inaccurate or unsuccessful closure of distal bronchioles
or alveolar spaces, are innocuous and of short dura-
tion.1,2 Persisting excessive air leaks, however, repre-
sent a major complication because they extend chest
tube drainage, length of hospital stay, overall morbidity,
and health care costs.1-5
Background: Air leaks after pulmonary resections may contribute to
increased patient morbidity, delayed removal of chest drainage tubes,
and prolonged hospitalization. Objective: The purpose of this study was
to investigate the effects of a new synthetic, absorbable sealant on the
healing of healthy bronchial and lung tissues (experimental study) and
its safety and efficacy to stop air leaks after lung resection (clinical
study). Methods: Fifteen large white pigs underwent a left upper lobecto-
my. All parenchymal surgical sites were sealed; the bronchial stump was
either stapled, sealed, or both (n = 5 each). In the clinical study, 26 con-
secutive patients were prospectively randomized, intraoperatively, to
standard closure of parenchymal surgical sites with (n = 15) or without
(n = 11) the sealant. Results: In the experimental study, no postoperative
air leaks occurred, with intact bronchial closures and normal tissues at
death. In the clinical study, 100% of intraoperative leaks were sealed
versus 18% of control patients (P = .001). Although 77% (n = 10) of
treated patients remained leak-free from the end of the operation to
chest tube removal versus 9% (n = 1) of control patients (P = .001), there
was no statistical difference in the duration of postoperative chest tube
time, hospital stay, or cost. There were no acute or late undesirable side-
effects related to the sealant application. Conclusions: The surgical adhe-
sive investigated here demonstrated a compelling safety profile and sig-
nificant clinical efficacy to stop air leaks after lung resections. (J Thorac
Cardiovasc Surg 1999;117:751-8)
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EXPERIMENTAL AND CLINICAL EVALUATION OF A NEW SYNTHETIC, ABSORBABLE SEALANT TO
REDUCE AIR LEAKS IN THORACIC OPERATIONS
ride (20 mg/kg intramuscularly) and inhalation of isoflurane
by mask as needed to enable endotracheal intubation. A sur-
gical plane of anesthesia was maintained using isoflurane
(1%-3% as needed) delivered through a semiclosed rebreath-
ing system. Perioperative antibiotics (cefazolin, 22 mg/kg
intravenously) were initiated at induction. Lactated Ringer’s
solution was given at 22 mg/kg/h through a marginal ear vein
during the surgical procedure. The animals were positioned in
right lateral decubitus position, and the thoracic cavity was
entered through the fourth intercostal space. The fissure
between the left upper and lower lobes was divided with a lin-
ear cutting stapler (TA 55; United States Surgical
Corporation, Auto Suture Company Division, Norwalk,
Conn); the vascular supply was ligated, and the left upper
lobe bronchus was divided. Depending on study group, the
bronchus was either stapled with a 30-mm mechanical stapler
(groups 1 and 2) or incised primarily approximately 4 mm
from the lobar take-off origin (group 3). Group 1 animals
received no additional treatment after the stapling of the
bronchial stump. Group 2 animals had approximately 2 to 3
mL of hydrogel sealant applied and polymerized over the sta-
ple closure. Group 3 animals had no suture or staple closure
and had a 4 to 5 mm open bronchial stump into which 2 to 3
mL of hydrogel sealant was applied and polymerized. All
bronchial closures were leak tested to 40 cm H2O, the tho-
racic cavity was thoroughly lavaged, fluid was evaluated, a
16F chest tube was placed, and the wound was closed in lay-
ers. The chest tube was intermittently monitored for air and
fluid output over 48 hours. Thoracic radiographs were taken
on postoperative days 3 and 5. Postoperative oral cephalo-
sporin antibiotics were continued for 7 days. Animals were
killed at 6 weeks; the trachea was harvested at the origin of
the left upper lobe bronchus, and porcine tissues were paraf-
fin embedded, processed, and stained with hematoxylin and
eosin. 
Clinical study. This open-labeled, randomized study was
conducted in accordance with the Medical Device Directive
and the European Standard (EN 540) for clinical investiga-
tion of medical devices for human subjects (British Standards
Institution publication, 615.471: 615.478: 620.1; 1993, pp.
62-78). The protocol was approved by the Paris-Sud
University and Marie-Lannelongue Ethics Committees and
operations were made by 2 of us (P.M. and P.D.). All consec-
utive patients scheduled for pulmonary lobectomy or lesser
resection by a thoracotomy between July 1996 and January
1997 were screened for eligibility to enter the study within 2
weeks of their operation; witnessed, informed consent was
obtained before the procedure. Inclusion criteria included age
(‡ 18 years); platelets (‡ 100,000 cells/mm3); alanine amino-
transferase, aspertate aminotransferase, and alkaline phos-
752 Macchiarini et al The Journal of Thoracic and
Cardiovascular Surgery
April 1999
A
B
Fig 1. The surgical sealant components (A) and life cycle (B).
phatase levels (≤1.5 of upper limit of normal); bilirubin level
(≤1.5 mg/dL); creatinine level (≤2.0 mg/dL); prothrombin
time (≤15 seconds), and patient ability to provide informed
consent. Any woman of child-bearing age required a negative
pregnancy test (human chorionic gonadotropin urine or
serum) within 7 days before the operation. The following
patients were excluded: patients undergoing pneumonecto-
my, women who were pregnant or lactating, patients with a
history or laboratory evidence of hemostatic abnormality or a
lack of hemostasis at operation, patients not expected to be
available for follow-up, patients who had undergone investi-
gational therapy within 28 days before the operation or who
were scheduled to receive such therapy within 30 days of the
operation, and any patient with severe congestive heart fail-
ure, cor pulmonale, and/or renal failure.
Patients enrolled in the study underwent their scheduled
thoracic procedure, during which the determination was made
as to whether they remained eligible for randomization. After
a lobectomy or lesser resection with standard suture and/or
staple closure, all surgical sites were identified. A surgical site
was defined as any site that had been manipulated and was
assumed to be at risk for air leakage, including all staple lines,
suture lines, areas of dissection and adhesiolysis. Next, sterile
saline solution was poured into the chest cavity; the lung was
submerged in the saline solution to check for the presence or
absence of air bubbles, and the location of each surgical site
was recorded. Each surgical site was graded with the lung sub-
mersed in saline solution and inflated to pressures of 20 to 40
cm H2O; the presence or absence of air leaks was scored as
grades 0 (no leak), 1 (countable bubbles), 2 (stream of bub-
bles), and 3 (coalesced bubbles). If any grade 3 leaks were
identified, the investigator used suture or stapler to close the
leak or at least reduce it to a lower grade; saline-solution sub-
mersion was repeated, and the final grade was recorded.
The randomization scheme was prepared by the study
statistician, and the randomization for each patient was main-
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Fig 2. The section taken just proximal to the sealant plug
(arrow) shows an organized fibrovascular scar that is bridg-
ing across and filling the entire bronchial lumen (note hyaline
cartilage lower right and left side of frame). The sealants pre-
sent right center frame surrounded by a cuff of macrophages;
note the lack of foreign body giant cell formation and viable
cells in contact with it. (Hematoxylin and eosin stain; origi-
nal magnification, · 25.)
Table I. Intraoperative characteristics of the experi-
mental study*
Characteristics Group I Group II Group III
Weight (kg) 22 ± 2 21 ± 2 20 ± 2
Left upper lobe surface (cm3) 1 ± 0.1 1 ± 0.1 0.9 ± 0.1
Left upper lobe stump length 1.5 1.3 ± 0.4 1.5 ± 0.3
(cm)
Light cycles
Lung stapler line 2 ± 1 2 ± 1 3 ± 1
Bronchial stump — 3 ± 1 2.4 ± 0.5
*Each study group included 5 animals.
Table II. Baseline characteristics of patients included
in clinical study
Treatment Control 
Characteristics (n = 13) (n = 11) P value
Gender
Male (%) 9 (69) 9 (82) .65
Female (%) 4 (31) 2 (18)
Age (mean ± SD y) 61 ± 10.3 59 ± 15.4 .93
Chronic obstructive (+ vs –) 2 vs 11 0 vs 11 .48
pulmonary disease
Chronic bronchitis (+ vs –) 1 vs 12 0 vs 11 1.0
Emphysema (+ vs –) 0 vs 13 1 vs 10 .46
Primary diagnosis .46
Bronchogenic carcinoma 9 (69) 7 (64)
(%)
Pulmonary metastases (%) — 2 (18)
Benign neoplasm (%) 2 (15) —
Bronchostenosis (%) 1 (8) —
Tuberculosis (%) 1 (8) 1 (9)
Other (%) — 1 (9)
+, Present; –, absent.
tained in a sealed envelope. After the grading of surgical sites
for leaks, the envelopes were sequentially opened, and the
patient was entered into either the treatment or control group
of the study. Patients assigned to the control group received
standard surgical management. Patients assigned to the treat-
ment group had the synthetic sealant applied to all identified
surgical sites (including those sites graded 0, nonleaking),
excluding the bronchial stump, followed by a repeat saline-
solution submersion test. If any leaks persisted or if new sites
were identified, additional sealant was applied as necessary.
A final submersion test was performed, and a posttreatment
grade for each identified site was recorded. 
On postoperative days 1, 3, 7 (and/or day of discharge), 30,
and 60, all patients underwent a safety evaluation including
an assessment of daily chest tube output. Safety evaluations
included physical examinations to monitor for potential aller-
gic or inflammatory reactions or compromised wound heal-
ing. Serum chemistries and hematologic parameters were
used to assess renal and liver functions or any unanticipated
toxicity. A further safety evaluation was made 18 months
after the operation for those patients who were still alive and
included all examinations mentioned.
Sealant material. The surgical lung sealant (Focal Inc,
Lexington) is a synthetic absorbable biomaterial consisting of
2 components, a primer and the sealant. The primary compo-
nent of the sealant is a difunctional macromonomer com-
posed of polyethyleneglycol, linked to trimethylene carbon-
ate moieties, which are in turn linked to acrylate endgroups
(Fig 1, A). The primer is reconstituted at the time of operation
and, when brushed onto the target tissue through the applica-
tor, acts as a wetting solution to prepare the surface of tissue
for good adhesion. The clear liquid polymer is delivered and
mixed into the primer, then a bead of the polymer is applied
from the applicator over the target tissue to form a thin coat-
ing that, when photopolymerized by visible light, forms a
biocompatible, elastic hydrogel patch. Photopolymerization
is accomplished by formulating the macromers in buffered
saline solutions containing triethanolamine and eosin Y as the
photoinitiator. Visible light illumination from a xenon arc
lamp (470-520 nm) at an intensity of 100 mW/cm2 is used to
initiate polymerization for 40 seconds. The sealant is about
80% water by weight and acts as a flexible, mechanical leak-
age barrier for 14 days, allowing full tissue expansion and
normal tissue healing at the treated site. Once implanted, the
sealant material degrades by hydrolysis (Fig 1, B), releasing
biocompatible components that are metabolized or cleared by
the kidneys. The rates of property and mass loss are deter-
mined by the hydrolyzable linkage, and the material under-
goes a characteristic and predictable breakdown pattern.
Statistics. All patients were evaluated for safety and effi-
cacy, with the exception of the 2 pilot patients, who were
evaluated for safety only. The safety profile was determined
by comparing the frequency and severity of adverse device
effects between treatment and control groups. The primary
efficacy criteria in the prevention of air leaks was investigat-
ed by 2 outcomes: evaluation of the efficacy in sealing air
leaks identified during operation and comparison of the dura-
tion of chest tube air leak between treatment and control
groups. Although secondary efficacy end points included the
time from operation to chest tube removal and to hospital dis-
charge, hospitalization time, and costs, this initial study was
not designed to have substantial impact on standard postop-
erative procedures or sufficient sample size to detect a differ-
ence between treatment and control groups with respect to
the secondary end points. The sample size, calculated for the
primary study end point of preventing postoperative air leaks,
was based on pre-existing data2 and the hypothesis that, on a
particular day (expected to be day 3 or 4), the proportion of
the treatment group patients with air leaks would be reduced
from 30% to 10% as compared with the control group.
All statistical comparisons were based on 2-sided P values
and used an a level of .05. Variables measured on a continu-
ous scale were analyzed with the Wilcoxon rank sum test.8
All categoric variables were analyzed with Fisher’s exact or
Pearson’s c 2 test.9 The distributions of time to last air leak
sealed and time to last chest tube removal were compared
with the log rank test and the generalized Wilcoxon test.8 The
distributions of laboratory severity grades were analyzed with
each patient’s highest postoperation laboratory grade (day 1-
discharge). Comparisons with respect to maximum postoper-
ation grade included only patients whose baseline value was
in the normal range and were carried out with the Mantel-
Haenszel c 2 test.10 The mean hospitalization cost per patient
was calculated according to the French National Cost Study
(DH/PMSI/92, No. 8 from February 28, 1992), which takes
into account the direct expenses affected to the individual
patient, expenses of the medical and technical procedures,
hospitalization expenses registered in the different clinical
units attended by the patient, and administrative and structur-
al expenses. However, it does not include the costs of the
sealant, which is distributed in Europe for the reduction of air
leaks after pulmonary operation by Ethicon, Inc (Johnson &
Johnson; AdvaSeal) at approximately $450 per kit; the equip-
ment is provided free of charge. 
The manufacturer (Focal, Inc) provided customary finan-
cial support only to offset the administrative costs of con-
ducting this study.
Results
Experimental study. The intraoperative characteris-
tics were not significantly different among the 3 groups
754 Macchiarini et al The Journal of Thoracic and
Cardiovascular Surgery
April 1999
Table III. Distribution of number of surgical sites per
patient
No. of Treatment Control 
surgical sites (n = 13) (n = 11)
0 — —
1 — —
2 — 1 (9)
3 (%) 5 (38) 4 (36)
4+ (%) 8 (62) 6 (55)
(Table I). None of the animals experienced infection,
dyspnea, or discomfort during the study period. No
postoperative air leaks occurred. Endoscopically, the
bronchial stumps showed mucosal apposition with no
evidence of fistulas in groups 1 and 2. Group 3 animals
showed an intact and clear, visible sealant that was
tightly adherent to the bronchial mucosa on days 3 and
5; a neomucosa had formed across its surface re-estab-
lishing mucosal continuity of the bronchial stump on
day 42. 
Group 1 and 2 histopathologic examination showed a
fibrous union of the bronchial walls and a healed
mucosa, with no difference in the degree of inflamma-
tion or quality of the healed bronchial closure. Tissues
examined from group 3 showed that a fibrous scar
developed over the sealant on both the bronchial and
pleural space surfaces. This fibrous tissue joined the
mucosal/submucosal layers across the hydrogel-filled
space between the bronchial walls. The sealant was still
present at 6 weeks and showed no cellular or microbial
ingrowth; the interface between the tissue and sealant
showed scattered, individual macrophages in contact
with the sealant surrounded by a 6- to 10-cell layer of
fibrovascular tissue (Fig 2). No foreign body giant
cells, polymorphonuclear leukocytes, or lymphocytes
were evident. A bridging neomucosa was present lying
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Table IV. Distribution of leaks by surgical sites (before randomization)
Type of leak Treatment sites (n) Leaks* (n) Control sites (n) Leaks† (n) Total sites (n) Leaks‡ (n)
Staple line (%) 30 13 (43) 35 15 (43) 65 28 (43)
Suture line (%) 3 2 (67) 2 1 (50) 5 3 (60)
Area of dissection (%) 22 14 (64) 10 5 (50) 32 19 (59)
Other 2 — — — 2 —
TOTAL (%) 57 29 (51) 47 21 (45) 104 50 (48)
*n = 13.
†n = 11.
‡n = 24.
Table V. Distribution of prerandomization air leak
grades
Treatment Control 
Grade (n = 13) (n = 11)
0 (%) 28 (49) 26 (55)
1 (%) 12 (21) 15 (32)
2 (%) 17 (30) 6 (13)
Table VI. Chest tube and hospital data
Treatment Control 
(n = 13) (n = 11) P values
Time from operation to 1.9 ± 1.2 2.4 ± 1.7 .2
last air leak sealed (d)
Time to removal of last 6.1 ± 0.8 6.9 ± 1.5 .9
chest tube (d)
Chest tube drainage 213.2 ± 31.1 91 ± 23.3 .6
per day (mL)
Hospitalization time (d) 13 ± 2.5 14.4 ± 5.2 .4
Hospitalization cost ($) 12,374 ± 2,416 13,637 ± 3,340 .3
Data are expressed as mean ± standard deviation. The calculation of the hos-
pital costs per day was made by taking $1 as 5.983 francs (June 10, 1998).
Table VII. Laboratory severity grades after operation
(among patients with normal baseline values)
Highest 
postoperative Treatment Control Mantel-Haenszel 
grade (%) (%) P value
AP .08
0 6 (43) 10 (91)
1 7 (50) —
2 1 (7) 1 (9)
3 — —
4 — —
AST .8
0 6 (43) 8 (73)
1 8 (57) 1 (9)
2 — 1 (9)
3 — —
4 — 1 (9)
ALT .8
0 8 (53) 6 (67)
1 5 (33) 2 (22)
2 2 (13) —
3 — —
4 — 1 (11)
Creatinine .2
0 15 (100) 8 (89)
1 — 1 (11)
2 — —
3 — —
4 — —
AP, Alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine
aminotransferase.
minutes; P = .14). The average amount of primer and
sealant applied per patient was 2.2 ± 1.5 mL and 6.2 ±
4.1 mL, respectively; and the average application time
was 15 ± 4.8 minutes. Intraoperative leaks were sealed
in 100% of treatment group patients versus 18% of
control group patients (P = .001). Postoperative chest
tube monitoring revealed that 77% (n = 10) of treat-
ment group patients remained leak free from the end of
the operation to chest tube removal versus 9% (n = 1)
of control group patients (P = .001). The proportion of
patients still experiencing leakage in the treatment
group was significantly (P = .02) lower immediately
after the operation, but this difference was not signifi-
cant at later times (P = .27). Treatment group patients
had a nonsignificant tendency to a shorter chest tube
time and hospitalization time and costs (Table VI).
A transient increase in alkaline phosphatase, aspartate
aminotransferase, alanine aminotransferase, and creati-
nine levels was noted; all increases resolved without
additional intervention or treatment. When comparing
the treatment and control groups with respect to highest
postoperation laboratory grade (excluding patients with
abnormal baseline values), no statistically significant
differences were found for any of the laboratory pa-
rameters (Table VII). There was no in-hospital death.
A major complication included 1 case (3.8%) of
emphyema (Pseudomonas aeruginosa) resulting in an
early bronchopleural fistula in a pilot group patient.
After an open window thoracostomy, a completion
pneumonectomy was necessary because of the erosion
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on and supported by the thin fibrovascular tissue in
contact with the hydrogel.
Clinical study. During the study period, a total of 30
patients were eligible for enrollment in the study; 4
patients (13%) were ineligible because they required a
pneumonectomy. Of the remaining 26 patients, 15
patients were assigned to the treatment (2 pilot patients
and 13 randomized patients), and 11 patients were
assigned to the control group; the two groups were
comparable according to their baseline characteristics
(Table II). 
Lobectomy was the primary procedure for both
groups (10 treatment and 3 control), followed by 1
treatment bilobectomy and 5 wedge resections (2 treat-
ment and 3 control). Overall, there was no statistically
significant difference between the treatment and con-
trol groups with respect to the number of surgical sites
per patient (P = .83; Table III). After the baseline
saline-solution submersion test and reduction of grade
3 leaks before the randomization, only 1 patient (8%) in
the treatment group and 2 patients (18%) in the control
group had no air leaks (P = .58). Table IV shows that
staple-line leaks (43%) were less frequently observed
than suture-line (60%) and dissection leaks (59%) (P =
.22). There was no statistically significant difference in
the overall distribution of prerandomization air leak
grades (P = .09; Table V).
Surgical time, excluding the surgical sealant applica-
tion time, did not significantly differ between the treat-
ment and control groups (142 ± 13 minutes vs 114 ± 11
Fig 3. High-power field of the inflammatory reaction against the sealant 19 days after the operation. As in our
preclinical experience, the sealant (*) was surrounded by a cuff of large macrophages, fibroblasts, and lympho-
cytes. (Hematoxylin and eosin stain; original magnification, · 40.)
of the pulmonary artery stump, but no evidence was
found to relate this complication to the application of
the sealant (Fig 3). At long-term follow-up (18 months),
there were no clinical, radiologic, or biologic signs of
adverse reactions related to the sealant application.
Discussion
An ideal sealant would incorporate a synthetic mater-
ial, avoiding the immunogenicity and risks of disease
transmission associated with human- or animal-sourced
material such as fibrin- or collagen-based products. For
use on pulmonary tissue, it would also allow for expan-
sion, resulting in a uniform surface load on the lung and
decreasing the potential for “secondary” tearing of fri-
able tissue adjacent to a treated site. It should also be
strong enough to remain sealed, withstanding normally
expected pressures of a lung inflated to 30 or 40 cm
H2O. It would be easy to apply and could be used to
treat air leaks from staple lines, sutures, and areas of
dissection not amenable to suture or staple closure. 
The sealant evaluated in this study is totally synthet-
ic and adheres well to the applied tissues. The hydro-
gel is polymerized in situ with 2 parts, a primer and a
sealant, as a laminate, forming a highly adherent coat-
ing of any desired thickness on the tissue. A laminate
structure is used to provide good bonding to tissue
(primer layer) and good mechanical properties (sealant
layer) for sealing the leak and maintaining the seal
during lung movement. The materials are applied to
tissue in aqueous solution formulations. The primer
solution is first brushed onto the tissue. The brushing
action allows the primer material to obtain good inti-
mate contact with the tissue surface, replacing the sur-
face moisture. The sealant material is then gently mixed
with the primer with a brush to provide a transition
layer between the primer and sealant layers. The final,
thicker sealant layer is then flowed over the applica-
tion area, and the laminate is photopolymerized.
Preclinically, it was shown to adhere 4 times more and
withstand pressures 12 times greater than could be tol-
erated by reference surgical sealant materials (Focal
Inc; personal communication, 1998). Once polymer-
ized, the sealant is clear, allowing good visualization
of target tissue. It has a compliance matched to human
lung tissue (28 vs 29.4 kPa, respectively) and the capa-
bility to expand to over 700% its own size, ensuring
that neither the sealant nor the lung tissue is torn dur-
ing respiration and that the lung tissue beneath the
sealant is normally ventilated. Histologic evaluation of
the immunogenicity of the sealant material has been
shown in preclinical studies to be similar to that seen
with suture materials.11
In the present experience, the synthetic sealant was
totally effective in eliminating intraoperative air leaks.
In the experimental study, the sealant was able to avoid
postoperative leaks arising from the dissected lung tis-
sues and the bronchial stumps. Interestingly, the stapled
lung tissues were always normal. The bronchoscopic
examinations showed an intact seal bridging the walls
of the bronchial stump on days 3 and 5 after the opera-
tion and a respiratory neomucosa re-epithelializing the
adhesive surface at death, with no evidence of cellular
or microbial ingrowth. This and its safe biologic profile
renders the investigated sealant particularly attractive
for a potential clinical application in treating bron-
chopleural fistulas. However, a recent yet unpublished
clinical study investigating the preventive effects of the
sealant on the bronchial stump after lobectomy was
associated with a high incidence of bronchopleural fis-
tula. A plausible explanation of this evidence could be
that the synthetic sealant applied to the bronchial stump
acted as a mechanical barrier preventing adhesion for-
mation and eliminating a natural source of revascular-
ization, resulting in slower healing therefore favoring
the genesis of bronchopleural fistula. However, our pre-
liminary experience with patients with postpneumonec-
tomy or postlobectomy bronchopleural fistulas is
encouraging because the application of the sealant
avoided the hazards of the postpneumonectomy
bronchial stump mediastinal dissection12 and resulted in
a long-lasting closure and no undesirable local or sys-
temic side effects (personal communication, 1998). 
In the clinical study, the sealant was easy to use and
apply in all anatomic areas, did not elicit a clinically
demonstrable host response, and did not result in any
significant changes in laboratory parameters necessitat-
ing interventional treatment across the varied study
population included in the treatment group. Intra-
operatively, the material remained clear, adherent, and
expandable and was able to eliminate all air leaks on
normal and diseased lung tissue. After the operation,
the proportion of patients who were air-leak free was
significantly higher in the treatment group, suggesting
that the sealant maintained its adhesive properties over
time. Although there was a tendency toward a shorter
chest tube time and hospitalization time and costs in
treated patients, this trend did not reach statistical sig-
nificance in our study. These end points are currently
under clinical investigation in a large, multi-institution-
al trial in the United States.
In conclusion, the sealant device investigated here
achieved the intended performance as a soft tissue rein-
forcement to be used for sealing or reducing air leaks
that occur during pulmonary operation. 
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